# Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure

Study · id `cardio:ct-nct03437226` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03437226](<https://clinicaltrials.gov/study/NCT03437226>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03437226

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.

## Technical summary

Registry record NCT03437226. Randomized; triple masking; primary purpose treatment. Start 2018-03-08 (actual); primary completion 2019-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 264 participants (planned count; ClinicalTrials.gov record NCT03437226, source copy `cardio:ctgov-nct03437226-2018-08-22`, retrieved 2026-10-26)
- Started: 2018-03-08 (actual) (ClinicalTrials.gov record NCT03437226, source copy `cardio:ctgov-nct03437226-2018-08-22`, retrieved 2026-10-26)
- Primary completion: 2019-04-01 (anticipated) (ClinicalTrials.gov record NCT03437226, source copy `cardio:ctgov-nct03437226-2018-08-22`, retrieved 2026-10-26)
- Completion: 2019-12-31 (anticipated) (ClinicalTrials.gov record NCT03437226, source copy `cardio:ctgov-nct03437226-2018-08-22`, retrieved 2026-10-26)
- Countries: Austria (ClinicalTrials.gov record NCT03437226, source copy `cardio:ctgov-nct03437226-2018-08-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03437226-2018-08-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
- Acronym: LeoDOR
- Condition: Heart Failure
- Intervention (Drug): Levosimendan 2.5 MG/ML
- Intervention (Drug): Placebos
- Lead sponsor: Dr. Gerhard Pölzl
- Lead sponsor class: OTHER
- Collaborator: Orion Corporation, Orion Pharma
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as a collaborator: Orion Corporation, Orion Pharma (`cardio:org-orion-corporation-orion-pharma`)

## Provenance

Content hash: 082c94a8ee1a13763f3d296e83939798b007679fa5699d80b426c7f6f4ca9154
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
